Respiratory diseases drugs market
covers drugs that are used in the treatment of a wide range of respiratory
diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic
and acute bronchitis, emphysema and cystic fibrosis. Some of the major drugs in
the market include antimuscarinics, corticosteroids, Codral, Coldrex and Lemsip.
Order report at
The global respiratory diseases
drugs market has shown moderate growth in the past years with a CAGR of
just over 6%. The year 2017 recorded highest ever market value in this industry
as per TBRC’s inhouse consultants.
TBRC’s latest report show the historic and future trends in
the market for each year with sourced reasons to support the growth claims.
The report also shows the respiratory
diseases drugs market to grow at a much higher CAGR by 2021 as compared
to 2017, along with geographies best suited for investments with highest return
rate.
Download sample
report at
China had the highest CAGR of more
than 15% during 2013-2017; this country is expected to grow at the same CAGR by
2021. The highest historic growth was due to increase in tobacco smoking, air
pollution levels and aging population in China and these factors are also
expected to drive the respiratory drugs market in future. In 2016, China
registered a total of 33.5 million cases of asthma, which is second highest in
the world. In addition, China is ranked 5th on the global pollution index, and
the air pollution levels are expected to rise in the forecast period thus
increasing the cases of respiratory diseases.
Countries included in the report are GlaxosmithKline Plc, AstraZeneca Plc, Merck & Co, Novartis AG, and Johnson
& Johnson.
The
Business Research Company is a Business Intelligence Company which excels in
company, market and consumer research. It has offices in the UK, the US and
India and a network of trained researchers in 15 countries globally.
Contact Information
The
Business Research Company
Europe:
+44 207 1930 708
Asia: +91
8897263534
Americas:
+1 315 623 0293
No comments:
Post a Comment